ArticleNature communications2026
Transcription factor 19 modulates fatty acid elongation and unfolded protein response to attenuate palmitic acid-induced hepatic dysfunction.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Saturated fatty acids, which increase during high-fat diets and metabolic disease, disrupt lipid homoeostasis, leading to hepatic dysfunction. Understanding how hepatocytes adapt to this stress is essential for delineating the early events of fatty liver disease and its progression to more severe inflammation and fibrosis. Here, we show that the transcription factor TCF19 acts as a central regulator that helps hepatocytes manage lipid overload and cellular stress in both MAFLD mice model and human clinical samples. Combining lipidomic and transcriptomic analysis, we found that TCF19 controls genes involved in fatty-acid elongation and protein-folding responses, thereby linking lipid metabolism with endoplasmic-reticulum stress-response pathways. Elevated TCF19 levels are associated with lipid accumulation, whereas reducing TCF19 worsens inflammation and fibrotic features of the liver. Together, our findings identify TCF19 as a protective regulator during the transition from early hepatic fat accumulation to inflammatory liver disease, highlighting a potential target for early therapeutic intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.